KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medicine and Oncology / 2021 / Cilt: 5 - Sayı: 3

Impact of Gender on the Prognosis of Patients withHepatocellular Carcinoma After Palliative Therapy

Lei LIU
Hao Tian LIU
Xiu Mei LIANG
Xu LIU
Zhu Jian DENG
Liang MA
Bangde XIANG
Jian Hong ZHONG
De Jia HUANG
Sayfa
222–227
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Results: Overall, the two groups did not have significant sex-related differences in prognosis for overall survival (OS)of palliative care, including transarterial chemoembolization (TACE), chemotherapy, and best supportive care (BSC).Using multivariate analysis, the following were identified as independent risk factors of survival (P

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Sex differences are ascribed to the risk of hepatocellular carcinoma (HCC); however, whether gender dis parity also exists in the prognosis of palliative therapy is yet unclear.
📊
Temel Bulgular & Veri:Methods: This retrospective cohort study consisted of 2356 patients (270 women and 2086 men) with a diagnosis ofHCC between 2006 and 2011.
💡
Sonuç & Katkı:Results: Overall, the two groups did not have significant sex-related differences in prognosis for overall survival (OS)of palliative care, including transarterial chemoembolization (TACE), chemotherapy, and best supportive care (BSC).Using multivariate analysis, the following were identified as independent risk factors of survival (P
🔬Tür:Araştırma Makalesi
📍Kapsam:2086 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Sex differences are ascribed to the risk of hepatocellular carcinoma (HCC); however, whether gender dis parity also exists in the prognosis of palliative therapy is yet unclear. A retrospective cohort study was performed toassess the prognostic predictors after palliative therapy of HCC, focusing on sex differences. Methods: This retrospective cohort study consisted of 2356 patients (270 women and 2086 men) with a diagnosis ofHCC between 2006 and 2011. The patients received palliative care. Clinical and laboratory data were evaluated andcompared. Results: Overall, the two groups did not have significant sex-related differences in prognosis for overall survival (OS)of palliative care, including transarterial chemoembolization (TACE), chemotherapy, and best supportive care (BSC).Using multivariate analysis, the following were identified as independent risk factors of survival (P

🔖

Bu Makaleye Atıf Yap

LIU, L., LIU, H. T., LIANG, X. M., LIU, X., DENG, Z. J., MA, L., XIANG, B., ZHONG, J. H., HUANG, D. J. (2022). Impact of Gender on the Prognosis of Patients withHepatocellular Carcinoma After Palliative Therapy. Eurasian Journal of Medicine and Oncology, Cilt: 5 - Sayı: 3, 222–227. https://ajindex.com/articles/509477

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018
  2. 394–424. [CrossRef] 2. Villa E, Baldini GM, Pasquinelli C, Melegari M, Cariani E, Di Chirico G, ET AL. Risk factors for hepatocellular carcinoma in Italy. Male sex, hepatitis B virus, non-A non-B infection, and alcohol. Cancer 1988
  3. 611–5. [CrossRef] 3. Evert M, Dombrowski F. Hepatocellular carcinoma in the noncirrhotic liver. Pathologe 2008
  4. 47–52. [CrossRef] 4. Tavani A, Negri E, Parazzini F, Franceschi S, La Vecchia C. Female hormone utilisation and risk of hepatocellular carcinoma. Br J Cancer 1993
  5. 635–7. [CrossRef] 5. Zhu RX, Seto WK, Lai CL, Yuen MF. epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver 2016
  6. 332–9. [CrossRef] 6. Benvegnu L, Fattovich G, Noventa F, Tremolada F, Chemello L, Cecchetto A, et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study. Cancer 1994
  7. 2442–8. [CrossRef] 7. Ganne-Carrie N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau JM, Oberti F, et al
  8. for CIRRAL Group. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. J Hepatol 2018
  9. 1274–83. [CrossRef] 8. Tanaka K, Sakai H, Hashizume M, Hirohata T. Serum testosterone:estradiol ratio and the development of hepatocellular carcinoma among male cirrhotic patients. Cancer Res 2000
  10. 5106–10. 9. Groupe d'Etude et de Traitement du Carcinome H. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen. Hepatology 2004
  11. 1361–9. [CrossRef] 10. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007
  12. 121–4. 11. Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a genderspecific risk factor for liver cancer? Hepatology. 2007
  13. 1304– 5. [CrossRef] 12. Hiraoka A, Michitaka K, Kumada T, Izumi N, Kadoya M, Kokudo N, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in japan: the need for a more detailed evaluation of hepatic function. Liver Cancer 2017
  14. 325–36. [CrossRef] 13. Yau T, Tang VY, Yao TJ, Fan ST, Lo CM, Poon RT. Development of Hong Kong Liver Ca